KAYS’ Fifth Dimension Therapeutics Plans to Open “The Sacred Mushroom” Psilocybin Centers in Oregon, Marking Entry into the Global Psychedelics Market, which is Forecast to Exceed $8 Billion by 2029.

FT. LAUDERDALE, FL / ACCESSWIRE / May 24, 2023 / Kaya Holdings, Inc., (“KAYS” or the “Company”) (OTCQB:KAYS), congratulates Bryan Arnold, a dedicated 9-year Kaya employee and Vice President with KAYS subsidiary Fifth Dimension Therapeutics, Inc. (“FDT”), for being among the first graduates of the Changa Institute and among the first ten (10) state Licensed Psilocybin Facilitators in the United States. The Company is proud of Bryan and look forward to his contribution as we seek to develop and launch “The Sacred Mushroom” Psilocybin Centers in accordance with Oregon State law.

As reported by Bloomberg in July of 2022, “the rise in stress levels and the growing rate of chronic diseases throughout the world is predicted to propel the global psychedelic medicines market expansion… the value of the Global Psychedelic Therapeutic Market is expected to grow from US$ 3.61 billion in 2021 to US$8.31 billion by 2028, with a CAGR of 13.2%.”

In January 2023 KAYS announced the launch of its FDT subsidiary to provide psychedelic “mind care” treatments to veterans suffering from PTSD, addicts seeking to break addiction, individuals with eating disorders, and people with treatment resistant depression and other mental health disorders. We are pleased to report this milestone and will update shareholders as we move forward with our plans to open our first Psilocybin Service Center to service the growing Psychedelics Market.

“An uncomfortable fact is that approximately every 40 seconds someone around the world commits suicide,” stated W. David Jones, KAYS Senior Advisor for Business Development and Financial Operations. “Picture a football stadium filled with 65,000 fans. That’s how many people die from suicide every month, and this doesn’t even consider the toll on the millions of family members and friends who are left behind, or the more than 100 million people struggling through their lives because of ineffectual mental health treatments” continued Jones. “We are moving to establish a unique facility dedicated to helping people leverage the power of psychedelics for richer, fuller, and more joyful living, pursuant to Oregon Health Authority requirements and statutes.”

“My experiences at the Changa Institute transformed my understanding of psychedelics”, says Bryan Arnold, Vice President of the Company’s Psychedelic unit. “I have gained a tremendous respect for the power of psychedelics and am excited by the potential it has to help people with certain mental health conditions. Being part of the KAYS team introducing psychedelics to the people of Oregon is both a responsibility and an honor, and The Sacred Mushroom will reflect our deep respect for psychedelics and the potential they hold to help or heal,” Arnold continues.

Changa Institute Graduates First Licensed US Psychedelic Facilitators:

https://psychedelichealth.co.uk/2023/04/03/changa-institute-first-licensed-us-psychedelic-facilitators/

Updated Information about Kaya Holdings, Inc. http://icont.ac/4QBdX

Kaya Holdings, Inc. (OTCQB:KAYS) is a Mind Care Company with longstanding operations as a touch-the-plant, vertically integrated legal cannabis business. The Company is evolving into a full mind care enterprise with the planned introduction of psilocybin and ketamine treatments, as permitted by State Law, as we seek to expand our medical cannabis business overseas. KAYS is a fully reporting, US-based publicly traded company, listed for trading on the OTCQB Tier of the over-the-counter market under the symbol KAYS.

Shareholder Hotline: For more information, please call 954-480-1270 or email info@kayaholdings.com to speak with our new Corporate Communications Manager regarding your investment in KAYS.

KAYS SHAREHOLDERS AND OTHER INTERESTED PARTIES – PLEASE UPDATE YOUR CONTACT INFORMATION

We routinely receive calls and emails from shareholders asking us questions about KAYS, so we are asking all KAYS shareholders to email us and confirm their contact info. Please email info@kayaholdings.com with “KAYS shareholder update” in the subject line and include your name, address, phone number and number of shares you own so that we may make sure you receive all updates and can respond to any shareholder inquiries.

Summary of Operations

KAYS corporate structure includes the following four majority-owned subsidiaries, each responding to various demands and opportunities in the cannabis or psychedelic industry:

Fifth Dimension Therapeutics, Inc. , serves as the Company’s operating branch to the psychedelic treatment sector, including operation of mushroom cultivation facilities and in-facility treatment centers.

Marijuana Holdings Americas, Inc. owns the Kaya Shack brand of licensed medical and recreational marijuana stores (www.kayashack.com) and the Kaya Farms brand of cannabis production and processing operations that operate in the United States.

Kaya Brands International, Inc., serves as the vehicle for the Company’s non-U.S. operations including cultivation activities in Greece and Israel.

Kaya Brands USA, Inc. owns a wide range of proprietary brands of cannabis extracts, oils, pre-rolls, topicals, edibles and beverages, cannaceuticals and related accessories.

Important Disclosure
KAYS is planning execution of its stated business objectives in accordance with current understanding of state and local laws and federal enforcement policies and priorities as it relates to cannabis and psychedelics. Potential investors and shareholders are cautioned that KAYS and subsidiaries including FTD will obtain advice of counsel prior to actualizing any portion of their business plan (including but not limited to license applications for the cultivation, distribution or sale of marijuana and psychedelic products, engaging in said activities or acquiring existing production/sales operations). Advice of counsel with regard to specific activities of KAYS, federal, state or local legal action or changes in federal government policy and/or state and local laws may adversely affect business operations and shareholder value. Success of our business plan including the launch of “The Sacred Mushroom” Psilocybin Facilitation Centers depends on many factors including receipt of requisite funding to build out and staff the Centers.

Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company’s current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE: Kaya Holdings, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

In Colorado, for example, the following conditions are state-approved for medical marijuana treatment:

• Cachexia (a condition typically caused by a disease like cancer or AIDS that causes significant weight loss, including muscle loss)
• Cancer
• Glaucoma
• HIV or AIDS
• Persistent muscle spasms
• Seizures
• Severe pain
• Post Traumatic Stress Disorder

Notice anything about that list? Except for PTSD, all of those conditions are primarily physical. 

The relationship between mental health and cannabis use is less clear. The U.S. drug war and decades of misinformation have biased the perception of cannabis use in mainstream medicine and culture.

Is Cannabis an Effective Treatment for Depression?

Thanks to nearly a century of federal cannabis prohibition making most plant studies illegal, there’s a lot about the cannabis plant that we just don’t know.

Study after study shows a correlation between cannabis use and depression, though prohibitionists or federal organizations sometimes use them to discourage cannabis use.

However, as more scientific studies are released and peer-reviewed by unbiased sources, it’s becoming increasingly clear that cannabis may be an effective treatment for the 280 million people in the world who suffer from depression.

Anecdotally, you can look at a longstanding cannabis review site like Leafly.com to see their database includes thousands of strains that users say positively affect depression and anxiety. Scientifically, recent studies released in The Journal of Biology and Medicine and Journal of Affective Disorders found that cannabis use provided great relief to those suffering from depression. 

There’s still plenty of work needed to get to the bottom of marijuana’s actual effects. But based on what we know now, here are five cannabis strains likely to help with symptoms associated with depression—like sadness, insomnia, a lack of energy, low concentration, and appetite loss.

Gelato

Cannabis enthusiasts prize the Gelato strain for its THC rate of 17% and uplifting effects. More than 2,000 people have ranked the strain at Leafly.com’s strain database—with “euphoric,” “aroused,” and “happy” being the top three good feelings they associate with it. 

About a quarter of Leafly’s reviewers said it aids in their depression (24%) and anxiety (26%), while 27% told the site that it’s a good destresser.

Photo: MmeEmil via gettyimages.com

Sherbert

If feeling relaxed, happy, and giggly sounds like a good alternative to your current mood, you’ll want to hit up your nearest dispensary for the Sherbert strain. 

“This strain exhibits powerful, full-body effects that are elevated by a jolt of cerebral energy and carefree state of mind,” Leafly’s in-house strain reviewers say. Its 18% THC rate “makes it an ideal choice for medical marijuana patients seeking relief from symptoms associated with stress, tension and mood disorders.”

Twenty-seven percent of users told Leafly that it helped with their anxiety and depression, respectively, while a whopping 35% said it’s a good stress reliever.

Thin Mint

Thirty percent of Leafly’s users told the company that the Thin Mint strain aids their depression, while 35% said it is a good destresser and 26% said it helps with pain—that’s a medical trifecta. It’s also a trifecta in a different sense, as the strain itself is a cross between sativa Durban Poison, indica OG Kush, and hybrid strain GSC (“Girl Scout Cookie”).

“Uplifted,” “euphoric,” and “relaxed” were users’ three highest-ranked feelings.

Dosidos

If you think you’re noticing a food theme here when it comes to strain names, welcome to the world of cannabis! And let’s talk about eating. Of course, cannabis is famous for its “munchy” effects, but some strains are more potent than others when creating an appetite. 

And being that a lack of appetite can be a sign of depression, what better solution than a strain known for making people hungry? And when “sleepy” and “relaxed” are the other two highest-ranking feelings in the Leafly database, it must be time to grab yourself an eighth of Dosidos.

Skunkberry

No mood-altering list of cannabis strains would be complete without a skunk on it. Yes, the skunk strains are known for smelling like, well, a skunk. They’re also famous for their euphoric and simultaneously pain-relieving high. 

At Leafly’s database, “relaxed,” “euphoric,” and “happy” were the highest-ranked feelings for the Skunkberry strain. About a third of reviewers told the website that Skunkberry helps with pain, stress, and depression. 

The next time you’re feeling a bit down, you might find some relief in alleviating your depression symptoms with one of these top-rated strains.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) set out to build a nationwide network of psychedelic-assisted psychotherapy clinics in 2018. Since then, the company has grown its footprint to ten clinics across six states exceeding 60,650 sq. ft. of space and clinical capacity for more than 120 treatment rooms, with more to come.

The company believes that each treatment room could accommodate up to four visits per day at $490 per visit. Using these assumptions, the company’s 120+ treatment rooms could generate upwards of $60 million in annual revenue. 

These estimates aren’t merely guesses, either. The company recently reported $1.55 million in revenue and an estimated $1.17 million in gross income for the ten months leading up to October 31, 2021. These figures were double those from one year ago and come mainly from organic growth at its flagship clinic in Knoxville, TN.

Beyond Physical Clinics

Revitalist hasn’t limited its focus to physical clinics. Next year, the company plans to launch its telemedicine platform targeting psychedelic therapies. As a result, the company could reach millions more people around the country beyond the reach of its network of clinics and provide better support to those who go into its clinics.

In November, the company also announced the acquisition of a 60% interest in Revitaland Meta Tech Inc. to create virtual clinics in the metaverse. The virtual world will enable patients and medical professionals to interact without being in the same physical space, improving accessibility without compromising the experience.

While the metaverse may seem far-fetched to many, Facebook’s move to rename its business “Meta” underscores just how central the concept is to tech giants. In addition, the COVID-19 pandemic and the rise of remote working are also pushing many consumers toward virtual meetings in the metaverse that could quickly become a ubiquitous environment.

Significant Potential

Revitalist’s significant progress in building out its physical and virtual clinic network and presence reflects the strength of its leadership team. In addition to its unparalleled medical expertise, the team includes veteran financiers and project managers that have a track record of growing $100+ million businesses.

CEO Katie Walker discusses the company’s growth strategy

Management hopes to build a network of nearly 50 clinics in 2022 before reaching more than 150 clinics by 2025. After establishing a footprint in the U.S., the company aims to expand to international locations in jurisdictions. These ambitions could yield a company generating upwards of $100 million in annual revenue at attractive gross margins.

And, while these plans may seem ambitious on the surface, Stifel GMP research suggests that psychedelic-assisted psychotherapy (PAP) clinics have a total addressable market of over $10 billion in the U.S. alone. As a result, the company has significantly greater potential than its immediate plans over the long term to capitalize on the massive market.

Looking Ahead

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) represents a compelling opportunity to invest in the growth of psychedelic-assisted therapies—a field that many experts believe could revolutionize mental health treatments worldwide. As the company continues to expand, investors may want to take a closer look at the stock.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Research study follows deployment of Cognetivity’s ICA in Ketamine One’s North American clinics and will open up novel, tailored use cases in burgeoning mental health market

VANCOUVER, BC, Dec. 2, 2021 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity“) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) today announced that it is entering into a collaborative partnership with KetamineOne Capital Ltd (“Ketamine One“) to study and develop assessments for depression and post-traumatic stress disorder (“PTSD“).

In the initial stage of the partnership, Cogentivity and Ketamine One will partner on two separate clinical studies, one for depression and the second for PTSD. Protocols for both studies have received Institutional Review Board (“IRB“) approval and patient recruitment is expected to occur in early 2022. Ketamine One’s wholly owned subsidiary, KGK Science Inc., will lead the study, while Cognetivity will lead the analysis.

Ketamine One is a next-generation health and wellness company focused on transforming the treatment of mental health through the provision of ketamine-assisted therapy and psychedelic medicines. Based in Canada and operating clinics throughout North America, the firm is dedicated to building the critical infrastructure needed to provide breakthrough and life-changing treatments for conditions such as anxiety, depression, PTSD, chronic pain and addiction.

Cognetivity’s Integrated Cognitive Assessment (“ICA“) technology has already been deployed throughout Ketamine One’s network of clinics in North America after the two companies entered into a commercial agreement earlier this year. In the latest phase of their collaboration, the ICA will be used to monitor changes in patients’ cognitive ability as they undergo ketamine-assisted treatment for depression and PTSD.

The clinical studies will add to the extensive body of data validating the ICA’s use as a cognitive testing tool. It has already been widely deployed in clinical care, from North America and the Middle East to clinics in the UK’s National Health Service. The project will also generate novel intellectual property regarding the ICA’s predictive and long-term monitoring capabilities – not only on a stand-alone basis, but in combination with additional variables, including data from wearable devices, to support the creation of dedicated new products for specialist care in the areas of depression and PTSD.

It is well known that there is vast potential for improvement in the treatment of such conditions. According to the WHO, mental health disorders account for 28% of the global burden of disability-adjusted life years among non-communicable diseases – more than cardiovascular disease or cancer. Every year, more than 12 billion working days are lost due to mental health conditions, costing the global economy USD 16 trillion in economic output between 2011 and 2030. The global market for PTSD therapeutics is expected to reach USD 3.1 billion by 2027, with the global market for the treatment of anxiety disorders and depression predicted to exceed 13 billion by the same year.

“We’re delighted to be extending our relationship with Cognetivity through this exciting new research project,” said Adam Deffett, Interim CEO of Ketamine One. “Depression and PTSD are sadly very common conditions and existing approaches to treating them leave a lot to be desired. With the crucial involvement of the ICA, this study will further demonstrate the power of our therapies as we pursue our goal of changing how mental health is treated across North America.”

Also commenting on the announcement, Dr Sina Habibi, CEO of Cognetivity, said, “It’s great to be working with Ketamine One on these clinical studies. We are very excited about obtaining high-quality clinical validation data on the use of the ICA to assess and monitor patients with depression and PTSD, and developing exciting new technology to better serve this important market. These disease areas represent important use cases for the ICA beyond its core application as a clinical tool for early detection of cognitive impairment. Expanding into applications such as this demonstrates the strength of the technology’s fundamental capabilities and the ongoing global need for much-improved cognitive testing across a huge number of areas.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.

About Ketamine One

KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

For more information, please visit: www.ketamine.one.

ON BEHALF OF THE BOARD
“Sina Habibi”
Sina Habibi
Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

Certain statements included in this news release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “assume” “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Cognetivity Neurosciences Ltd

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Post-traumatic stress disorder, or PTSD, is a common mental illness among veterans. According to the Department of Veteran Affairs, 11% to 30% of veterans who served in foreign wars experience PTSD, far higher than the estimated 6% of the general population. PTSD manifests in many ways, ranging from depression to chronic fatigue.

The FDA’s decision to approve Spravato, an esketamine nasal spray, to treat depression and suicidal ideations marked the beginning of a psychedelic revolution in mental healthcare. Researchers believe that ketamine could also play a role in treating other mental health conditions, including PTSD and its many symptoms.

Let’s take a look at ketamine’s promise in treating PTSD and how KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (FFT: MY0) (“Ketamine One” or the “Company”) aims to bring treatments to veterans and other sufferers of mental health conditions.

Ketamine Shows Promise

Ketamine has shown the potential to treat PTSD in several clinical studies. 

For example, a 2014 study found that intravenous ketamine was associated with significant and rapid reductions in PTSD symptom severity, compared with midazolam, when assessed 24 hours after infusion. In addition, researchers reported that the treatment was generally well-tolerated without persistent dissociative symptoms.

More recently, a 2021 study conducted by Mount Sinai researchers found that repeated infusions with ketamine over two weeks significantly reduced symptom severity in many patients while also helping minimize depression symptoms. While improvement occurred after just 24 hours, the benefit was “significantly greater” at two weeks and lasted ~30 days.

Bringing Treatments to Veterans

Ketamine infusion centers are becoming increasingly common across North America.

For example, Ketamine One (NEO: MEDI) (OTC: KONEF) (FFT: MY0) recently signed a non-binding letter of intent with Veteran Services USA to lease 5,000 sq. ft. of space over five years in Blue Island, Illinois, to provide ketamine-assisted therapies. Its goal is to create a first-of-its-kind healing experience for veterans who have PTSD.

“We are very proud to be part of an important project such as this with Veteran Services USA, which will allow KetamineOne to showcase its innovative approach to care and treatment by addressing veterans’ unique needs,” said Interim CEO Adam Deffett. “Our company sees an immediate need for its services and has a special opportunity to help.”

Part of a Broader Picture

Ketamine’s potential is just starting to be realized, and the Company plans to build a leading network of clinics.

 There are more than 200 active clinical trials involving ketamine in the United States, according to ClinicalTrials.gov. Researchers are evaluating the breakthrough drug to treat conditions like epilepsy, bipolar depression, postpartum depression, perinatal depression, cognitive dysfunction, autism spectrum disorder, and countless other conditions. 

In the meantime, Ketamine One (NEO: MEDI) (OTC: KONEF) (FFT: MY0) aims to consolidate medical clinics and become a North American leader in mental health treatments. Currently, the Company has 16 clinics across North America and acquired a contract research organization (CRO) to expand into the clinical side of the industry.

Looking Ahead

Ketamine has shown tremendous potential for treating PTSD, but that’s just scratching the surface of what’s possible.

Ketamine One’s (NEO: MEDI) (OTC: KONEF) (FFT: MY0) acquisition of KGK Science, a CRO, brings 24 years of experience across pharmaceuticals, cannabis, and emerging psychedelics. In conjunction with its network of clinics, the company is well-positioned to become a leader in conducting cutting-edge clinical research in the space.

For more information, visit the Company’s website or download their investor presentation.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated.

MedXtractor Corp.’s (CSE: MXT) (OTC: MXTTF) SHAMAN and YMI programs apply machine learning to high-resolution health records to better diagnose mental health disorders. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Let’s take a closer look at the challenges facing mental health treatments and how SHAMAN and psychedelics could play critical roles in improving them.

Mental Health Challenges

Mental health disorders affect a high percentage of the population. For example, mood and anxiety disorders affect nearly one-third of the U.S. population. In addition, a relatively high rate of people experiencing these conditions visit their primary care physician with physical complaints, like fatigue, creating an opportunity for diagnosis and treatment.

Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. For example, research shows that primary care physicians misdiagnosed 65.9% of patients with major depressive disorder, 92.7% of patients with bipolar disorder, 71% of patients with generalized anxiety disorder, and 97.8% of patients with social anxiety disorder.

Even if there’s an accurate diagnosis, many mental health treatments have less-than-desirable efficacy, and there can be significant side effects. Psychedelics could offer a better alternative for many patients. Still, years of prohibition have set back clinical trials, and there’s not a lot of information about how and when to administer these kinds of treatments.

Psychedelics Provide a Solution

Psychedelics have been used for thousands of years in religious ceremonies and as part of various cultures. These days, over 30 million people in the U.S. have used psychedelics for mystical experiences, curiosity, and introspection. The widespread use has made it clear that they don’t cause organ damage, withdrawal symptoms, or elicit compulsive use.

Researchers are just starting to uncover the potential for psychedelics to treat mental health disorders. For example, in a small study of adults with major depression, Johns Hopkins researchers found that two doses of psilocybin with psychotherapy produced rapid and significant reductions in depressive symptoms. Half of the participants were in complete remission through four weeks.

Despite the tremendous promise of psychedelics, there are no large-scale standardized clinical trials or data sources that clinicians can use to guide their patient decisions. Many studies thus far involve only a small number of participants and have a minimal focus without an eye toward mainstream applications at a clinical level.

Building the Data Backend

MedXtractor is leveraging machine learning to predict the impact of psychedelics and psychotropics on mental health disorders through its SHAMAN program. With extensive and ever-expanding validated data, the platform can provide high-resolution opinions on the probabilities related to many mental health afflictions.

Psychedelics and psychotropics and their potential application to mental health afflictions are SHAMAN’s initial target. In mid-June, the company announced that it has collected more than 400 complete reference records and is on track to reach its target of 500 complete reference records by June 30, 2021.

The company hopes to reach its Phase 3 target of 800 reference records by the end of August and launch the platform in December. In the meantime, management is focused on tight cost controls to keep project costs under budget while developing mHeath applications and their bio-extraction business operations.

Looking Ahead

Mental health disorders cost the global economy trillions of dollars each year, but screening, diagnosis, and treatment remain largely ineffective despite their prevalence. Psychedelics could play a role in turning around these trends, but clinicians require more data to properly diagnose patients and determine if psychedelic therapies are suitable for them.

MedXtractor Corp. (CSE: MXT) (OTC: MXTTF) is leveraging machine learning to garner insights from hundreds of complete medical records. Using these insights, the company hopes to provide high-resolution opinions on the probabilities related to many mental health afflictions.

Investors may want to take a closer look at the stock as it continues to collect complete reference records ahead of its launch late this year. For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The psychedelics industry has experienced a renaissance over the past few years as researchers have opened a pandora’s box of potential. From major depression to generalized anxiety to post-traumatic stress disorder, emerging research suggests that psychedelic substances could have a significant beneficial impact on hard-to-treat mental health disorders.

As states liberalize their psychedelics regulations, microdosing has become a popular trend that could offer a variety of mental health benefits. Research on microdosing remains in its infancy, but the combination of placebo-controlled studies and effective delivery systems could translate to a larger-scale trend over the coming years.

Let’s take a closer look at microdosing and how new technologies are making it easier to achieve a consistent result.

What is Microdosing?

Microdosing is the practice of consuming a very low, sub-hallucinogenic dose of a psychedelic substance, such as psilocybin or LSD. While scientific literature contains minimal research, there is plenty of anecdotal evidence to support the practice but the handful of high-quality studies that do exist paint a mixed picture of microdosing efficacy.

In 2018, the Imperial College of London conducted the first placebo-controlled study of microdosing practices. Participants received either a psychedelic or placebo and completed online surveys and cognitive tasks at regular intervals. The results showed improvements in both the psychedelic and placebo groups with no significant differences between them.

Other researchers believe that microdosing may still offer tangible benefits. Maastricht University researchers in the Netherlands conducted their own small-scale placebo-controlled study and found beneficial effects on mood and attention for some participants that couldn’t be explained by the placebo effect. They suggest that timing could be an important factor.

The same researchers from Maastricht University measured brain-derived neurotrophic factor (BNDF)—a protein that affects brain plasticity—and found an increase a few hours after microdosing psychedelics in blood tests. These findings suggest that there is some kind of physiological factor at play with microdosing practices.

 Ensuring the Right Dose

The varying effects of microdosing practices could be the results of varying metabolic rates and drug delivery mechanisms. For instance, capsule-based forms of microdosing involve swallowing a pill that is subject to second-pass metabolism in the liver. Sublingual delivery mechanisms, on the other hand, quickly move to the brain. 

Revive Therapeutics Ltd. (CSE: RVV) is building an intellectual property portfolio around psychedelic drug delivery. After acquiring Psilocin Pharma Corp., the company partnered with Complete Phytochemical Solutions and signed a sponsored research deal with the University of Wisconsin-Madison to develop new delivery methods for psychedelic substances.

The company’s dissolvable oral strips could be especially beneficial for microdosing, delivering between one and 20 milligrams of natural or synthetic psilocybin with rapid onset that bypasses liver metabolism. The company’s other products targeting both psychedelics and cannabinoids include lozenges, gels, creams and transdermal patches. 

While many companies undergo expensive clinical trials, the company’s innovative delivery systems could see a faster path to commercialization as California, Oregon and other states start to legalize psychedelics for personal use. These efforts could open the door to widespread microdosing practices to realize cognitive and other mental health benefits.

Looking Ahead

Investors interested in the psychedelics space may want to consider companies focused on microdosing practices since they could represent a nearer-term path to commercialization. Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) is a prime example with its dissolvable oral strip delivery system for psilocybin microdosing.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

What is the ideal setting for a brand to showcase its wares to the retail consumer? It is certainly not a crowded store with hundreds of brands competing for limited shelf space and consumer attention. Every brand out there would much rather have its own store, featuring its own product offerings, staffed by expert sales associates ready to educate consumers on the value of their products. In short, every brand would like its own version of the Apple Store or the Gap. Of course, every brand can’t afford to develop its own store, and cannabis licensing requirements often make the idea even more untenable.

CalEthos may have the answer for cannabis brands struggling to solve this problem. The company is currently financing the first of several planned cannabis superstores, appropriately called SHOWCASE, in Southern California. The concept is to provide partner cannabis brands their own space within a 20,000 sq. ft. SHOWCASE footprint, allowing them to fully display all that a brand has to offer. Each SHOWCASE location will also feature a medical pharmacy, an event center for community and consumer education, and a cafe and lounge areas to enhance the consumer experience and extend the shopper’s stay. Rather than the cramped, hurried environment common throughout retail cannabis, SHOWCASE promises to cater to both the customer and the brand in an elevated, inviting space.

CalEthos President Piers Cooper sat down with CFN Media to discuss the ideal setting for retailers to SHOWCASE their cannabis brand. Please click on the video below for the full story.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

Click below to hear CalEthos’ President Piers Cooper discuss the SHOWCASE concept

CalEthos Did the Homework

The two executives largely responsible for the CalEthos concept, CEO Michael Campbell and President Piers Cooper, have a long history in advising, building, and investing in companies both private and public. They kept bumping up against the emerging cannabis industry and decided to investigate, looking for opportunities arising from shortcomings in the young marketplace. They settled on retail, visiting a wide variety of stores and brands and talking to everyone involved, from the consumer to the staff to the product companies.

These investigations highlighted the problems listed above, both for the brand and for the consumer. Cannabis has been legalized, but many stores still carry a bit of a black-market vibe which is uninviting to newer cannabis consumers. Space is at a premium, as most dispensaries don’t have the capital to build large format stores or expand and upgrade existing stores. Budtenders are generally helpful, but they are usually limited to some personal advice about a brand they like before making the sale and moving on to the next in line.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

From the brand side, it is almost impossible to build a loyal customer base under such conditions. With advertising options limited, brands don’t have anywhere to turn. A given dispensary may carry 5 out of the brand’s 50 SKUs, whilst those 5 products are generally displayed amongst many other brands with limited space or capability for differentiation.

Campbell and Cooper came away from their research knowing there had to be a solution that provided a better consumer experience while enabling product makers to actively engage and educate those consumers.

Click below to hear CalEthos’ President Piers Cooper discuss The SHOWCASE Model Inspiration

The SHOWCASE Solution

CalEthos enlisted the help of Stephen Brady, the man responsible for the design of numerous Ralph Lauren, Bloomingdales, Gap, Old Navy, Banana Republic and other retail stores. Brady helped them realize the vision of an open, engaging, vital retail setting in which consumers are given space and options and educational opportunities. CalEthos is tuned in to the need to invite and educate ‘canna-curious’ consumers, and the SHOWCASE design enables that with event and education space along with lounge areas and a cafe. The concept is not turn and burn, though there is nothing stopping a customer from grabbing what they need and leaving quickly. Rather, the concept is explore and learn and enjoy. CalEthos believes consumers will gravitate to its model over the typical marijuana dispensary in the Southern California market.

Rendering of CalEthos SHOWCASE retail store

The company already knows that brands will appreciate the opportunity to create their own stores-within-a-store. Brand partners can procure dedicated space under the SHOWCASE Brand Membership Program that ranges from a 10’ x 16’ boutique with 90’ of shelf space, to shared kiosks in specialty product sections with 21’ of shelf space per brand, to 18’ of refrigerated shelf space in the Chill Zone for edibles and beverages. The SHOWCASE design also features a pharmacy dedicated to medicinal cannabis products and to provide advice for consumers exploring alternative medical options offered by cannabis products. All spaces are staffed by associates who are highly trained on products sold in their display areas.

Ready to SHOWCASE your Brand? Click Here to Apply.

Click below to hear CalEthos’ President Piers Cooper discuss the CalEthos Event Center

Overall, the concept is compelling and a refreshing change from the typical dispensary environment. Southern California, with its advanced legal market, huge population, and trend-setting reputation, is a prime location for the SHOWCASE concept. Investors interested in learning more about the opportunity are encouraged to follow the links. The future of cannabis retail awaits.

For Additional Information on CalEthos Please Visit the website at: https://www.calethos.com

CalEthos

CEO Michael Campbell

[email protected]

714-352-5315

CFN Enterprises

President Frank Lane

206-369-7050

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a presence in the space. 

In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how Ehave Inc. (OTC: EHVVF) along with other public companies are positioning themselves in the psychedelic space.

A Growing Body of Evidence

A growing body of evidence supports the use of psychedelics to treat a variety of different medical conditions. In 2016, Johns Hopkins researchers found that psilocybin produced a substantial and sustained decrease in depression and anxiety in cancer patients. A follow-up study on the same patients five years later found lasting effects from the one-time therapy.

The therapeutic evidence has become so overwhelming that Johns Hopkins established the Center for Psychedelic and Consciousness Research earlier this year to start rigorously investigating the drugs’ therapeutic potential. Researchers believe that it could have a beneficial impact on everything from smoking addiction to Alzheimer’s disease.

In addition to medical benefits, there’s plenty of anecdotal evidence that microdoses of psychedelics could improve mental health, well-being and productivity. Many prominent business leaders in Silicon Valley, including the late Steve Jobs, praised the benefits of microdosing psychedelics for creativity and cognition.

Click here to receive Ehave News and Investor Updates

Decriminalization Gain Ground

The growing interest among researchers has bolstered attempts by activists to decriminalize psychedelics throughout the country. Denver, Oakland and Santa Cruz have already decriminalized psychedelics over the past year, while California, Oregon and Iowa could see psychedelic-related measures on the ballot in November.

In the nation’s capital, Rep. Alexandria Ocasio-Cortez, D-NY recently introduced legislation that would allow researchers to more easily study the therapeutic and medicinal benefits of psilocybin and other psychedelics. These developments mirror what happened in the early medical cannabis industry where regulations were slowly relaxed over time.

It’s worth noting that these early efforts seek to decriminalize psychedelics and pave the way for research. Unlike the cannabis industry, there’s less interest in a recreational market and more interest in building a viable alternative therapy for countless different medical conditions that impact the brain—many without any current options.

Investors Start Taking Notice

Mind Medicine Inc. (NEO: MMED), better known as MindMed, became the first psychedelic pharmaceutical company to go public earlier this year on the NEO exchange. After raising $24.2 million in pre-public funding, the company plans to initially focus on addressing the opioid crisis and other forms of addiction with the use of psychedelics.

Click here to receive Ehave News and Investor Updates

Ehave Inc. (OTC: EHVVF) is another publicly-traded company in the space. Its Mycotopia Therapy subsidiary recently acquired PsychedeliTech and plans on hosting an inaugural PsyTech Summit in Tel Aviv, Israel on June 14-15, 2020. The conference will be modeled after the highly-successful CannaTech conference and connect key industry participants.

The company believes that it’s Dash platform will play a crucial role in the global advancement of psychedelic research. As a HIPAA and GDPR compliant platform, Dash is secure and compliant with some of the world’s strictest privacy laws. It’s an optimal way to compile psychedelic research and results to provide easy access for scientists globally.

Looking Ahead

Psychedelics are quickly picking up steam among both researchers and investors. As the market opens up, forward-thinking companies are building an early presence in the space before it grows into a large and mainstream industry. Cannabis investors may want to consider building a position in some of these companies given the similarities.

Please click here for additional Information on EHave, Inc. (OTC: EHVVF)

Please click here for additional Information on Mycotopia Therapy

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

A big factor in the recent rise of cannabis legalization is the emergence of legitimate scientific research into the potential health benefits of the plant’s active ingredients, called cannabinoids. Medicines are often derived from naturally occurring compounds, from aspirin to insulin to penicillin. A decent body of research is currently pointing to psilocybin, the psychedelic active ingredient in some types of mushrooms, as well as other psychedelics like LSD, as the next big natural drug discovery. Researchers are in various stages of studying the effect of psychedelics on conditions ranging from depression to addiction to migraines to anxiety and more. It might be time to pay attention to the field as more researchers test the therapeutic potential of psychedelics.

One company certainly paying attention is EHave, Inc. (OTC: EHVVF). The company has developed a technology platform that helps doctors and patients make data-informed treatment decisions for a variety of mental health indications. With the formation of a subsidiary called Mycotopia Therapy and an initial acquisition of PsychedeliTech, the company is becoming a major player in the emerging psychedelic medicine space. The Ehave Dash, already HIPAA and GDPR compliant, will be used as a central clearinghouse for psychedelic research data and clinical trial tracking with the intent to further advance the science of psychedelic therapies.

Psychedelic Research Enters the Mainstream

Just last year, the Johns Hopkins School of Medicine opened the Center for Psychedelic and Consciousness Research in Baltimore. Headed by renowned researcher Roland R. Griffiths, Ph.D., the Center aims to further research the school has already been conducting. Initial areas of focus include potential therapies for opioid addiction, Alzheimer’s disease, PTSD, and anorexia among other conditions. Johns Hopkins researchers have been pioneers in the field as the first researchers, in 2000, to get US regulatory approval for the use of psychedelics in health volunteers. Since then, the school’s researchers have published more than 60 peer-reviewed studies and demonstrated safe practices for psychedelic research that have set the standard for other studies across the world.

There are plenty of other researchers pursuing potential psychedelic therapies. The University of Toronto Mississauga recently started a Psychedelic Studies Research Program. The British Columbia Centre on Substance Abuse is launching a Phase III clinical trial of MDMA as a treatment for PTSD, in conjunction with 16 other locations throughout North America and Israel, and funded by the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS). The MAPS site has comprehensive lists of research, both ongoing and completed, conducted by MAPS as well as other organizations. There is a lot of scientific interest in psychedelics, and it is growing exponentially.

EHave’s Plan

The PsychedeliTech acquisition is just the first step for EHave in a comprehensive plan to bring together the diverse and scattered research (and researchers) into one collaborative platform. PsychedeliTech is hosting the inaugural PsyTech Summit March 29-30, in Tel Aviv, Israel. Modeled after the hugely successful CannaTech conference, a global gathering for the cannabis industry. In fact, PsychedeliTech is a subsidiary of Israel Cannabis Limited (iCAN), the creator of the CannaTech conference, and the two conferences run back-to-back at the same location this year. 

The goal of the PsyTech Summit is to elevate the psychedelics conversation, foster normalization, and accelerate innovation. Why is EHave acquiring the company and the conference? Because its subsidiary, Mycotopia Therapy, was founded to work toward the same goals. EHave believes its EHave Dash platform can play a crucial role in the worldwide advancement of psychedelic research. The Dash is HIPAA and GDPR compliant, meaning that the data carried by the Dash is totally secure and in line with the world’s most strict privacy and security rules. The idea is to compile all psychedelic research and results in the EHave Dash, providing valuable and easily accessible information for scientists across the globe as they pursue their own studies.

The PsyTech Summit is a perfect vehicle for fostering crucial relationships with innovators in the space. It could also serve to introduce Mycotopia Therapy to other potential investments or acquisitions that fit under the company’s mission, as the PsyTech acquisition is just the first of many moves to come.

The Upshot

The story of psychedelics as therapeutic treatments is now unfolding across the world. There is a lot of promising research into a wide variety of problematic neurological and psychological conditions that have resisted more traditional treatments to date. It’s a potentially explosive industry in its infancy, and EHave is making moves to become a key cog in the industry’s development. Keep an eye out here for more news regarding both the company and the movement in general.

Please click here for additional Information on EHave, Inc. (OTC: EHVVF)

Please click here for additional Information on Mycotopia Therapy

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.